Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach

Experimental Hematology

Volumn 43, Issue 2, 2015, Pages 89-99

  Kiebala, Michelle ^a   Skalska, Jolanta ^b   Casulo, Carla ^a   Brookes, Paul S ^a   Peterson, Derick R ^a   Hilchey, Shannon P ^a   Dai, Yun ^c   Grant, Steven ^c   Maggirwar, Sanjay B ^a   Bernstein, Steven H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ALFRED UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; BUTHIONINE SULFOXIMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THIOREDOXIN REDUCTASE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; GLUTATHIONE; THIOREDOXIN; TXN PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, MANTLE-CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; PRIMARY CELL CULTURE; TUMOR CELL LINE;

ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; AURANOFIN; B-LYMPHOCYTES; BUTHIONINE SULFOXIMINE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY; NF-KAPPA B; OXIDATION-REDUCTION; OXIDATIVE STRESS; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS;

EID: 84925016308     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.10.004     Document Type: Article

References (55)

1. Sharma S.V., Settleman J. Exploiting the balance between life and death: Targeted cancer therapy and "oncogenic shock". Biochem Pharmacol 2010, 80:666-673.
2. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: Oncogene and nononcogene addiction. Cell 2009, 136:823-837.
3. Champion G.D., Cairns D.R., Bieri D., et al. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. J Rheumatol 1988, 15:28-34.
4. Williams H.J., Ward J.R., Egger M.J., et al. Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Cooperative systematic studies of rheumatic diseases. Clin Rheumatol 1984, 3(Suppl 1):39-50.
5. Furst D.E. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 1983, 3:284-298.
6. Brewer E.J., Giannini E.H., Person D.A. Early experiences with auranofin in juvenile rheumatoid arthritis. Am J Med 1983, 75:152-156.
7. Hull R.G., Morgan S.H., Parke A.L., Childs L., Goldman M., Hughes G.R. A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheumatoid arthritis previously stabilized on sodium aurothiomalate. Int J Clin Pharmacol Res 1984, 4:395-401.
8. Jessop J.D., O'Sullivan M.M., Lewis P.A., et al. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1998, 37:992-1002.
9. Mustacich D., Powis G. Thioredoxin reductase. Biochem J 2000, (346 Pt 1):1-8.
10. Kim N.H., Park H.J., Oh M.K., Kim I.S. Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep 2013, 46:59-64.
11. Marzano C., Gandin V., Folda A., Scutari G., Bindoli A., Rigobello M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 2007, 42:872-881.
12. Nakaya A., Sagawa M., Muto A., Uchida H., Ikeda Y., Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk Res 2011, 35:243-249.
13. Zalewski P.D., Forbes I.J., Valente L., Hurst N.P. Auranofin increases the affinity of phorbol dibutyrate receptors in chronic lymphocytic leukemia cells (B cells). J Immunol 1987, 138:3005-3009.
14. Mandal P.K., Schneider M., Kolle P., et al. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 2010, 70:9505-9514.
15. Griffith O.W. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 1982, 257:13704-13712.
16. Sobhakumari A., Love-Homan L., Fletcher E.V., et al. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One 2012, 7:e48175.
17. Fath M.A., Ahmad I.M., Smith C.J., Spence J., Spitz D.R. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res 2011, 17:6206-6217.
18. Antelmann H., Helmann J.D. Thiol-based redox switches and gene regulation. Antioxid Redox Signal 2011, 14:1049-1063.
19. Jeon K.I., Jeong J.Y., Jue D.M. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 2000, 164:5981-5989.
20. Jeon K.I., Byun M.S., Jue D.M. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med 2003, 35:61-66.
21. Namba M., Ohtsuki T., Mori M., et al. Establishment of five human myeloma cell lines. Vitro Cell Dev Biol 1989, 25:723-729.
22. Sniderhan L.F., Garcia-Bates T.M., Burgart M., Bernstein S.H., Phipps R.P., Maggirwar S.B. Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of nonHodgkin lymphoma. Exp Hematol 2009, 37:1295-1309.
23. Skalska J., Brookes P.S., Nadtochiy S.M., et al. Modulation of cell surface protein free thiols: A potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One 2009, 4:e8115.
24. Dai Y., Landowski T.H., Rosen S.T., Dent P., Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002, 100:3333-3343.
25. Schreiber E., Matthias P., Muller M.M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989, 17:6419.
26. Ramirez S.H., Sanchez J.F., Dimitri C.A., Gelbard H.A., Dewhurst S., Maggirwar S.B. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. J Neurochem 2001, 78:874-889.
27. Maggirwar S.B., Ramirez S., Tong N., Gelbard H.A., Dewhurst S. Functional interplay between nuclear factor-kappaB and c-Jun integrated by coactivator p300 determines the survival of nerve growth factor-dependent PC12 cells. J Neurochem 2000, 74:527-539.
28. Kiebala M., Polesskaya O., Yao Z., Perry S.W., Maggirwar S.B. Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. PLoS One 2010, 5:e11875.
29. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998, 95:2509-2514.
30. Laska E.M., Meisner M., Siegel C. Simple designs and model-free tests for synergy. Biometrics 1994, 50:834-841.
31. Dasmahapatra G., Lembersky D., Son M.P., et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells invitro and invivo. Mol Cancer Ther 2012, 11:1122-1132.
32. Lu G., Xiao H., You H., et al. Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin Cancer Res 2008, 14:4981-4988.
33. Liu T., Yacoub R., Taliaferro-Smith L.D., et al. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther 2011, 10:1460-1469.
34. Cox A.G., Brown K.K., Arner E.S., Hampton M.B. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 2008, 76:1097-1109.
35. Rigobello M.P., Bindoli A. Mitochondrial thioredoxin reductase purification, inhibitor studies, and role in cell signaling. Methods Enzymol 2010, 474:109-122.
36. Rigobello M.P., Callegaro M.T., Barzon E., Benetti M., Bindoli A. Purification of mitochondrial thioredoxin reductase and its involvement in the redox regulation of membrane permeability. Free Radic Biol Med 1998, 24:370-376.
37. Rigobello M.P., Folda A., Baldoin M.C., Scutari G., Bindoli A. Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic Res 2005, 39:687-695.
38. Liu J.J., Liu Q., Wei H.L., Yi J., Zhao H.S., Gao L.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells. Pharmazie 2011, 66:440-444.
39. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011, 12:715-723.
40. Chen C., Edelstein L.C., Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000, 20:2687-2695.
41. Harhaj E.W., Sun S.C. Regulation of RelA subcellular localization by a putative nuclear export signal and p50. Mol Cell Biol 1999, 19:7088-7095.
42. Weir S.J., DeGennaro L.J., Austin C.P. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 2012, 72:1055-1058.
43. Spyrou G., Holmgren A. Deoxyribonucleoside triphosphate pools and growth of glutathione-depleted 3T6 mouse fibroblasts. Biochem Biophys Res Commun 1996, 220:42-46.
44. Oeckinghaus A., Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009, 1:a000034.
45. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
46. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent nonHodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
47. Richardson P.G., Xie W., Mitsiades C., et al. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009, 27:3518-3525.
48. Fabre C., Mimura N., Bobb K., et al. Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012, 18:4669-4681.
49. Gloire G., Piette J. Redox regulation of nuclear post-translational modifications during NF-kappaB activation. Antioxid Redox Signal 2009, 11:2209-2222.
50. Kabe Y., Ando K., Hirao S., Yoshida M., Handa H. Redox regulation of NF-kappaB activation: Distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 2005, 7:395-403.
51. Sun S.C. Non-canonical NF-kappaB signaling pathway. Cell Res 2011, 21:71-85.
52. Shih V.F., Tsui R., Caldwell A., Hoffmann A. A single NFkappaB system for both canonical and noncanonical signaling. Cell Res 2011, 21:86-102.
53. Rahal R., Frick M., Romero R., et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014, 20:87-92.
54. Bailey H.H., Ripple G., Tutsch K.D., et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997, 89:1789-1796.
55. O'Dwyer P.J., Hamilton T.C., LaCreta F.P., et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996, 14:249-256.